CTLA4 and gastric carcinoma: The use of immune checkpoint inhibitors like PD-1, PD-L1, and CTLA-4 has enhanced the survival outcomes for certain cancer patients, particularly those with malignant melanoma, gastric carcinoma, and hepatocellular carcinoma.